UNSPSC 51343305: Omaciclovir

This classification denotes an antiviral agent with the molecular formula C10H15N5O3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier C9H909GLI3, chemically known as 6h-purin-6-one, 2-amino-1,9-dihydro-9-(4-hydroxy-2-(hydroxymethyl)butyl)- (r)-; but generally known as omaciclovir, which bears US NIH Compound Identifier 3047801. The term OMACICLOVIR is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 15 No. 3-4, 2001, List 46). Most nations schedule omaciclovir under HS 29335995 and SITC 51576.

As of Q4 2014, OMACICLOVIR remains the US FDA Preferred Term for this commodity. Omaciclovir bears US NLM identifiers UMLS ID C2983879 and NCI Concept Code C90785. SMILES: C1=NC2=C(N1CC(CCO)CO)NC(=NC2=O)N.

UNSPSC 51343305 Omaciclovir is a Commodity code for antiviral pharmaceutical products, but recent state and local procurement activity under this code shows minimal direct alignment — the posted opportunities reflect purchases of unrelated medications (antibiotic and opioid-reversal drugs) rather than omaciclovir itself. State and local health departments and county public health agencies have used this code designation in warehouse procurement and pharmaceutical stockpiling initiatives, typically through piggyback or cooperative purchasing agreements with established pharmaceutical distributors. Issuing bodies include state-level health departments and county health authorities managing public health supply chains, often coordinating acquisitions through multi-agency consortiums like MMCAP to achieve volume pricing and streamlined procurement workflows.

The Illinois Department of Public Health awarded a $2,999,999.11 piggyback pharmaceutical warehouse contract to Chartwell Rx LLC through the MMCAP Infuse consortium in August 2026 for antibiotics (Doxycycline Hyclate 100mg and Ciprofloxacin Hydrochloride 500mg), and Seminole County, Florida released an IFB in June 2026 for annual procurement of 1,900 units of Naloxone and 800 Safe Drug Deactivation Systems with quarterly deliveries and a two-year initial term. Illinois and Florida show recent activity; however, the mismatch between the code's nominal scope and the actual products being purchased suggests either tagging inconsistency or that omaciclovir procurement activity does not currently drive state and local volume through this designation. Firms pursuing opportunities under this code should verify the actual pharmaceutical product specifications in each RFP or IFB, as the code label does not reliably predict what will be solicited.